# LUCA Science

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/luca-science

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.luca-science.com
- Total disclosed funding: $38M
- Latest round: Series B (Jun 6, 2022)
- Investors on record: 12

## About

LUCA Science Inc. is a biopharmaceutical company focused on developing functional mitochondria as therapeutic agents to repair damaged tissues and organs through innovative drug delivery technologies.LUCA Science Inc. was founded in 2018 and operates from its headquarters in Tokyo, Japan. The company specializes in creating therapies that target inherited mitochondrial diseases. As of June 2022, LUCA Science raised JPY 3.86 billion in Series B funding, co-led by Fast Track Initiative and 4BIO Capital Partners, with notable participation from several venture capital firms. The latest funding round has brought the total amount raised to JPY 3.86 billion, with a current valuation of JPY 4.27 billion. The CEO of the company is Rick Tsai.LUCA Science Inc. specializes in the development of functional mitochondria as therapeutic agents through a proprietary method that isolates these mitochondria. The company integrates advanced drug delivery technologies to deliver their mitochondrial therapies, primarily targeting inherited mitochondrial diseases. Their core products cater to healthcare providers and research institutions in Japan and the United States, focusing on areas where mitochondrial disorders are prevalent.LUCA Science operates under a revenue model emphasizing strategic partnerships and collaborations with research institutions and healthcare providers. Revenue is generated primarily through licensing agreements for their proprietary mitochondrial therapies and partnerships that facilitate the distribution of their innovative biopharmaceutical products. Collaborative arrangements may include co-development agreements or revenue-sharing models, ensuring that clients can integrate LUCA Science’s advancements into their therapeutic applications.In June 2022, LUCA Science Inc. successfully raised JPY 3.86 billion in Series B funding, which will be utilized to establish a manufacturing system for their biopharmaceutical agents. The company is focused on expanding into new markets, specifically targeting regions with high prevalence of mitochondrial diseases. Future product launches are anticipated as they continue to develop their therapeutic technologies, with an aim to enhance their market presence strategically.

## Funding rounds

- Series B, Jun 6, 2022, $29M — Daiwa Corporate Investment, Nippon Venture Capital, SMBC Venture Capital, Nissay Capital, Remiges Ventures, 4BIO Capital Partners, Fast Track Initiative, QB Capital, NCB Venture Capital, ASAHI KASEI PHARMA CORPORATION
- Series A, Sep 1, 2020, $9.7M — Nippon Venture Capital, Remiges Ventures, Fast Track Initiative, Axil Capital, Cahc co.,ltd.

## Investors

- Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series A, Series B
- Remiges Ventures (https://capitalatlas.ai/funds/remiges-ventures) — Series A, Series B
- Fast Track Initiative (https://capitalatlas.ai/funds/fast-track-initiative) — Series A, Series B
- Axil Capital (https://capitalatlas.ai/funds/axil-capital) — Series A
- Cahc co.,ltd. — Series A
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series B
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series B
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series B
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Series B
- QB Capital (https://capitalatlas.ai/funds/qb-capital) — Series B
- NCB Venture Capital (https://capitalatlas.ai/funds/ncb-venture-capital) — Series B
- ASAHI KASEI PHARMA CORPORATION — Series B